Neurogene’s (NGNE) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Neurogene (NASDAQ:NGNE) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $55.00 price objective on the stock. HC Wainwright also issued estimates for Neurogene’s Q4 2024 earnings at ($1.05) EPS, FY2024 earnings at ($4.34) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.19) EPS.

Several other equities analysts have also recently weighed in on the stock. Robert W. Baird increased their price objective on shares of Neurogene from $54.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 12th. Leerink Partners lifted their price target on shares of Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 12th. BMO Capital Markets cut their price objective on shares of Neurogene from $65.00 to $60.00 and set an “outperform” rating for the company in a research report on Tuesday, November 12th. Finally, Stifel Nicolaus raised their target price on Neurogene from $44.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurogene has a consensus rating of “Buy” and a consensus price target of $60.83.

Neurogene Stock Up 1.7 %

Shares of NGNE opened at $15.59 on Tuesday. Neurogene has a one year low of $12.49 and a one year high of $74.49. The business has a fifty day moving average of $45.41 and a 200 day moving average of $39.62.

Institutional Investors Weigh In On Neurogene

A number of institutional investors have recently bought and sold shares of NGNE. Quest Partners LLC purchased a new position in shares of Neurogene in the second quarter valued at about $55,000. BNP Paribas Financial Markets raised its stake in Neurogene by 192.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock valued at $91,000 after purchasing an additional 1,429 shares during the period. SG Americas Securities LLC purchased a new position in Neurogene in the 1st quarter worth approximately $120,000. MetLife Investment Management LLC purchased a new position in Neurogene in the 3rd quarter worth approximately $254,000. Finally, Jane Street Group LLC bought a new position in Neurogene in the 3rd quarter worth approximately $324,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.